Skip to content
DataLookout
Menu

NuPOWERNCT05935358

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

StatusRecruiting
PhasePhase 4
SponsorOctapharma
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
    • Primary and study completion dates pushed to Dec 2026
    • Secondary endpoints: details revised at 3 of 9 entries
    • Site details revised at 9 of 18 sites
    • Publications: details revised at 1 of 1 entry
  2. Minor Study completion date: Aug 2026 to Sep 2026v9
  3. Minor Site details revised at 1 of 18 sitesv8
  4. Notable Primary and study completion dates: Dec 2025 to Aug 2026v7
  5. Minor Study sites: 17 to 18v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 8 to 17v5
  2. Notable Eligibility criteria expanded, about 1 word
    • Study sites: 5 to 8
    • Start date changed from estimate of Feb 2024 to Nov 28, 2023
    • Secondary endpoints revised (9)
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2023 to Feb 2024
    • Study sites: 3 to 5
    v3
  4. Minor Study sites: 0 to 3v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall haemostatic efficacy
Timeframe: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Secondary (9)

Intraoperative haemostatic efficacy
Postoperative haemostatic efficacy
Blood product transfusion levels
FVIII plasma levels
Thrombin generation
Show 4 moreShow less
Perioperative haemostatic efficacy per World Federation of Hemophilia (WFH) criteria
Thrombotic events
FVIII inhibitor formation
Adverse events

Arms and interventions

NuwiqExperimental

All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.

Drugs: Nuwiq

Sites

18 sites in 11 countries

Germany 3, Italy 3, France 2, India 2, Spain 2, Croatia 1, Finland 1, North Macedonia 1, Serbia 1, United Kingdom 1, United States 1